- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00433381
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
Study Overview
Status
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of 6-month progression-free survival rate, in patients with recurrent or refractory intracranial glioblastoma multiforme or gliosarcoma.
II. Determine the adverse event profile and tolerability of bevacizumab and temozolomide in these patients.
SECONDARY OBJECTIVES:
I. Determine the efficacy of bevacizumab and temozolomide, in terms of 6-month progression-free survival rate, in patients previously treated with temozolomide.
II. Determine the efficacy of bevacizumab and irinotecan hydrochloride, in terms of objective response, in patients with measurable disease.
III. Determine the efficacy of bevacizumab and temozolomide, in terms of objective response, in patients with measurable disease who were previously treated with temozolomide.
IV. Determine the toxicity profile and tolerability of bevacizumab and irinotecan hydrochloride in these patients.
TERTIARY OBJECTIVES:
I. Assess the potential role of perfusion MRI and magnetic resonance spectroscopy imaging as an early indicator of response to therapy after 2 weeks of treatment with bevacizumab.
II. Assess the potential role of perfusion MRI and magnetic resonance spectroscopy imaging as a prognostic indicator based on images taken at baseline, at 2 weeks, and after 2 courses of study treatment.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (< 50 vs >= 50 years of age) and Karnofsky performance status (70-80% vs 90-100%). Patients are randomized to 1 of 2 treatment arms with a 2:1 ratio (arm I:arm II).
ARM I: Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
ARM II: Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
In both arms, treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. All patients undergo MRI at baseline and at every 2 courses (no 2-week MRI) per standard of care until progression or discontinuation of treatment to assess areas of breakdown of the blood-brain barrier. Patients undergo an additional MRI after study therapy. Consenting patients also undergo diffusion and perfusion MRI and magnetic resonance spectroscopic imaging for correlative studies.
After completion of study therapy, patients are followed up for at least 1 month.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 36607
- Mobile Infirmary Medical Center
-
-
Alaska
-
Fairbanks, Alaska, United States, 99701
- Fairbanks Memorial Hospital
-
-
Arizona
-
Scottsdale, Arizona, United States, 85260
- Arizona Oncology Services Foundation
-
-
California
-
Berkeley, California, United States, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Burlingame, California, United States, 94010
- Mills-Peninsula Medical Center
-
Concord, California, United States, 94520
- John Muir Medical Center-Concord Campus
-
Duarte, California, United States, 91010
- City of Hope Comprehensive Cancer Center
-
Greenbrae, California, United States, 94904
- Marin General Hospital
-
Novato, California, United States, 94945
- Sutter Cancer Research Consortium
-
San Francisco, California, United States, 94115
- California Pacific Medical Center-Pacific Campus
-
Vallejo, California, United States, 94589
- Sutter Solano Medical Center/Cancer Center
-
Walnut Creek, California, United States, 94598
- John Muir Medical Center-Walnut Creek
-
-
Connecticut
-
New Haven, Connecticut, United States, 06520
- Yale University
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Boca Raton Regional Hospital
-
Gainesville, Florida, United States, 32610
- University of Florida Health Science Center - Gainesville
-
-
Idaho
-
Boise, Idaho, United States, 83712
- Saint Luke's Mountain States Tumor Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- University of Chicago Comprehensive Cancer Center
-
-
Indiana
-
Anderson, Indiana, United States, 46016
- Saint Vincent Anderson Regional Hospital/Cancer Center
-
Beech Grove, Indiana, United States, 46107
- Franciscan Saint Francis Health-Beech Grove
-
Indianapolis, Indiana, United States, 46202
- IU Health Methodist Hospital
-
Richmond, Indiana, United States, 47374
- Reid Health
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Maryland
-
Annapolis, Maryland, United States, 21401
- Anne Arundel Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan Comprehensive Cancer Center
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
Kalamazoo, Michigan, United States, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, United States, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, United States, 49001
- Borgess Medical Center
-
Royal Oak, Michigan, United States, 48073
- William Beaumont Hospital-Royal Oak
-
-
Minnesota
-
Burnsville, Minnesota, United States, 55337
- Fairview Ridges Hospital
-
Coon Rapids, Minnesota, United States, 55433
- Mercy Hospital
-
Edina, Minnesota, United States, 55435
- Fairview-Southdale Hospital
-
Fridley, Minnesota, United States, 55432
- Unity Hospital
-
Maplewood, Minnesota, United States, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, United States, 55407
- Abbott-Northwestern Hospital
-
Robbinsdale, Minnesota, United States, 55422
- North Memorial Medical Health Center
-
Saint Louis Park, Minnesota, United States, 55416
- Park Nicollet Clinic - Saint Louis Park
-
Saint Paul, Minnesota, United States, 55102
- United Hospital
-
Waconia, Minnesota, United States, 55387
- Ridgeview Medical Center
-
Woodbury, Minnesota, United States, 55125
- Minnesota Oncology Hematology PA-Woodbury
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Montana
-
Billings, Montana, United States, 59101
- Northern Rockies Radiation Oncology Center
-
-
New Hampshire
-
Keene, New Hampshire, United States, 03431
- Cheshire Medical Center-Dartmouth-Hitchcock Keene
-
Lebanon, New Hampshire, United States, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Edison, New Jersey, United States, 08818
- John F Kennedy Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- New Mexico Oncology Hematology Consultants
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
Rochester, New York, United States, 14642
- University of Rochester
-
Rochester, New York, United States, 14620
- Highland Hospital
-
-
North Carolina
-
Asheville, North Carolina, United States, 28801
- Mission Hospital-Memorial Campus
-
Charlotte, North Carolina, United States, 28203
- Carolinas Medical Center/Levine Cancer Institute
-
-
Ohio
-
Akron, Ohio, United States, 44307
- Akron General Medical Center
-
Dayton, Ohio, United States, 45406
- Good Samaritan Hospital - Dayton
-
Dayton, Ohio, United States, 45409
- Miami Valley Hospital
-
Dayton, Ohio, United States, 45415
- Samaritan North Health Center
-
Dayton, Ohio, United States, 45420
- Dayton NCI Community Oncology Research Program
-
Dayton, Ohio, United States, 45405
- Grandview Hospital
-
Dayton, Ohio, United States, 45428
- Veteran Affairs Medical Center
-
Findlay, Ohio, United States, 45840
- Blanchard Valley Hospital
-
Franklin, Ohio, United States, 45005-1066
- Atrium Medical Center-Middletown Regional Hospital
-
Kettering, Ohio, United States, 45429
- Kettering Medical Center
-
Troy, Ohio, United States, 45373
- Upper Valley Medical Center
-
Xenia, Ohio, United States, 45385
- Greene Memorial Hospital
-
-
Oregon
-
Gresham, Oregon, United States, 97030
- Legacy Mount Hood Medical Center
-
Milwaukie, Oregon, United States, 97222
- Providence Milwaukie Hospital
-
Portland, Oregon, United States, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
Portland, Oregon, United States, 97225
- Providence Saint Vincent Medical Center
-
Portland, Oregon, United States, 97227
- Legacy Emanuel Hospital and Health Center
-
Portland, Oregon, United States, 97216
- Adventist Medical Center
-
Tualatin, Oregon, United States, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Thomas Jefferson University Hospital
-
Philadelphia, Pennsylvania, United States, 19103
- Radiation Therapy Oncology Group
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02903
- Rhode Island Hospital
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Utah
-
American Fork, Utah, United States, 84003
- American Fork Hospital / Huntsman Intermountain Cancer Center
-
Cedar City, Utah, United States, 84720
- Sandra L Maxwell Cancer Center
-
Murray, Utah, United States, 84107
- Intermountain Medical Center
-
Murray, Utah, United States, 84107
- Cottonwood Hospital Medical Center
-
Ogden, Utah, United States, 84403
- McKay-Dee Hospital Center
-
Provo, Utah, United States, 84604
- Utah Valley Regional Medical Center
-
Saint George, Utah, United States, 84770
- Dixie Medical Center Regional Cancer Center
-
Salt Lake City, Utah, United States, 84106
- Utah Cancer Specialists-Salt Lake City
-
Salt Lake City, Utah, United States, 84143
- LDS Hospital
-
Salt Lake City, Utah, United States, 84103
- Intermountain Health Care
-
-
Vermont
-
Saint Johnsbury, Vermont, United States, 05819
- Norris Cotton Cancer Center-North
-
-
Washington
-
Federal Way, Washington, United States, 98003
- Saint Francis Hospital
-
Kirkland, Washington, United States, 98033
- EvergreenHealth Medical Center
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle, Washington, United States, 98101
- Virginia Mason Medical Center
-
Vancouver, Washington, United States, 98664
- PeaceHealth Southwest Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin Hospital and Clinics
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert and The Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Histologically confirmed intracranial glioblastoma multiforme (GBM) or gliosarcoma
- Original histology of low-grade glioma with subsequent histological diagnosis of GBM or gliosarcoma allowed
Recurrent or refractory disease, meeting all of the following criteria:
- Must have received prior temozolomide
Pathologic or imaging confirmation of tumor progression or regrowth required
- Confirmation of true progressive disease (rather than radiation necrosis) by positron emission tomography, thallium scanning, MRI spectroscopy, or surgical documentation required for patients who received prior interstitial brachytherapy, Gliadel wafer, or stereotactic radiosurgery
- Unequivocal radiographic evidence of tumor progression by MRI within the past 14 days (while on a stable dose of steroids for ? 5 days)
No acute intratumoral hemorrhage on MRI
- Patients with MRI demonstrating old hemorrhage or subacute blood after a neurosurgical procedure (biopsy or resection) are eligible
- Karnofsky performance status 70-100%
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for at least 6 months after completion of bevacizumab therapy
- Systolic blood pressure ? 160 mm Hg or diastolic blood pressure ? 90 mm Hg (antihypertensive medication allowed)
- Able to undergo brain MRI scans with intravenous gadolinium
- Absolute neutrophil count ? 1,500 cells/mm?
- Platelet count ? 100,000 cells/mm?
- Hemoglobin ? 10 g/dL (transfusion or other intervention allowed)
- WBC ? 3,000 cells/mm?
- AST < 2 times upper limit of normal
- Bilirubin ? 1.6 mg/dL
- Creatinine < 1.5 mg/dL
- Urine protein:creatinine ratio ? 0.5 by urinalysis OR total urinary protein < 1,000 mg by 24-hour urine collection
- INR < 1.4 (for patients not on warfarin)
- No patients with severely impaired renal function (i.e., estimated glomerular filtration rate < 30 mL/min or on dialysis)
- No other prior invasive malignancy, except nonmelanomatous skin cancer or carcinoma in situ of the cervix, unless the patient has been disease free and off therapy for that disease for ? 3 years
No severe, active comorbidity, defined as any of the following:
- Transmural myocardial infarction or unstable angina within the past 6 months
- Evidence of recent myocardial infarction or ischemia manifested as ST elevation of ? 2 mm by EKG performed within the past 14 days
- New York Heart Association class II-IV congestive heart failure requiring hospitalization within the past 12 months
- History of stroke or transient ischemic attack within the past 6 months
- Cerebrovascular accident within the past 6 months
- Serious and inadequately controlled cardiac arrhythmia
- Significant vascular disease (e.g., aortic aneurysm or history of aortic dissection)
- Clinically significant peripheral vascular disease
- Evidence of bleeding diathesis or coagulopathy
- Serious or nonhealing wound, ulcer, or bone fracture
- Abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 28 days
- Acute bacterial or fungal infection requiring intravenous antibiotics at the time of study entry
- Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within the past 14 days
- Acquired immune deficiency syndrome (AIDS)
- No significant traumatic injury within the past 28 days
- No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
- No condition that impairs the ability to swallow pills (e.g., gastrointestinal tract disease resulting in an inability to take oral medication; requirement for IV alimentation; prior surgical procedures affecting absorption; or active peptic ulcer disease)
- No disease that would obscure toxicity or dangerously alter drug metabolism
- No concurrent major surgical procedures
- Recovered from prior therapy
Recent resection of recurrent or progressive tumor allowed provided the following criteria are met:
- Failed prior radiotherapy that was completed ? 42 days ago
- Residual disease after resection of recurrent glioblastoma is not mandated
- More than 28 days since prior surgery or open biopsy
- More than 7 days since prior core or needle biopsy
- At least 28 days since prior investigational agents
- At least 14 days since prior vincristine
- At least 42 days since prior nitrosoureas
- At least 21 days since prior procarbazine
- At least 28 days since other prior cytotoxic therapy
- At least 7 days since prior noncytotoxic agents (e.g., interferon, tamoxifen, thalidomide, or isotretinoin [except radiosensitizers])
At least 14 days since prior enzyme-inducing antiepileptic drugs (EIAEDs)
- Concurrent non-hepatic EIAEDs allowed
- No other concurrent CYP3A4 inducers, such as rifampin or Hypericum perforatum (St. John's wort)
Concurrent full-dose anticoagulants (e.g., warfarin or low molecular weight heparin) allowed provided all of the following criteria are met:
- No active bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)
- In-range INR (usually between 2 and 3) on a stable dose of oral anticoagulants or on a stable dose of low molecular weight heparin
- No concurrent highly active antiretroviral therapy
- No concurrent prophylactic use of growth factors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (bevacizumab and temozolomide)
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and oral temozolomide once daily on days 1-21.
|
Given IV
Other Names:
Given orally
Other Names:
|
Experimental: Arm II (bevacizumab & irinotecan hydrochloride)
Patients receive bevacizumab IV as in Arm I followed by irinotecan hydrochloride IV over 90 minutes on days 1 and 15.
|
Given IV
Other Names:
Given IV
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Irinotecan Hydrochloride Arm
Time Frame: From randomization to six months.
|
Progression defined as ≥ 25% increase in the size of enhancing tumor or any new tumor; or neurologically worse, and steroids stable or increased.
Percentage is calculated by taking the number of patients who have survived 6 months without progression of study disease after study registration in the numerator.
The denominator consists of all patients except those who were found retrospectively to be ineligible or who were lost to follow-up after less than 6 months.
|
From randomization to six months.
|
Count/Percentage of Patients Discontinuing Treatment Due to Treatment-related Medical Complications(Bevacizumab and Temozolomide Arm)
Time Frame: From randomization to end of treatment (treatment can continue up to 24 months for patients with stable or responding tumor).
|
This endpoint determines tolerability of this treatment arm.
If tolerable, then the secondary endpoint of treatment efficacy for this arm occurs.
Percentage is calculated by taking the number of patients who did not stop bevacizumab and temozolomide treatment due to medical complications in the numerator.
The denominator consists of all patients except those who were found retrospectively to be ineligible or who did not begin treatment.
|
From randomization to end of treatment (treatment can continue up to 24 months for patients with stable or responding tumor).
|
Number of Participants With Predicted Progression-free Survival at 6 Months (PFS-6)
Time Frame: 2 and 8 weeks posttreatment, and every 2 months until 96wks
|
Magnetic Resonance Imaging with Spectroscopy (MRS or MRSI) metabolic tumor ratios will be used to predict 6-month progression-free survival (PFS-6) over all study participants.
Ratios of NAA/Cho, Cho/Cr, NAA/Cr measured at 2 weeks and 8 weeks and every 2 months until 96wks were used to predict survival, and time to progression, evaluated at 96wks, is the determinate of PFS at 6months (PFS-6).
Subjects will not be analyzed by arm.
|
2 and 8 weeks posttreatment, and every 2 months until 96wks
|
Number of Participants With Predicted Overall Survival (OS) at 12 Months
Time Frame: 2 and 8 weeks posttreatment, and every 2 months until 96wks
|
Magnetic Resonance Imaging with Spectroscopy (MRS or MRSI) metabolic tumor ratios will be used to predict 12-month overall survival (OS). Ratios of NAA/Cho, Cho/Cr, NAA/Cr measured at 2 weeks and 8 weeks and every 2 months until 96wks were used to predict survival, and time to death, evaluated at 96wks, is the determinate of OS at 12 months. Subjects will not be analyzed by arm. |
2 and 8 weeks posttreatment, and every 2 months until 96wks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Count/Percentage of Patients Progression-free at 6 Months for Bevacizumab and Temozolomide Arm
Time Frame: From randomization to six months.
|
Progression defined as ≥ 25% increase in the size of enhancing tumor or any new tumor; or neurologically worse, and steroids stable or increased.
Percentage is calculated by taking the number of patients who have survived 6 months without progression of study disease after study registration in the numerator.
The denominator consists of all patients except those who were found retrospectively to be ineligible or who were lost to follow-up after less than 6 months.
|
From randomization to six months.
|
Patients' Best Objective Response (Complete Response, Partial Response, Stable Disease, Progression)
Time Frame: From randomization to death or last follow-up. Patients were followed up to 62.9 months.
|
Tumor size measured in millimeters and is the largest crosssectional area using perpendicular measurements of contrast enhancing abnormality.
Complete response (CR): Complete disappearance of all enhancing tumor on consecutive MRI scans at least 1 month apart, off corticosteroids, and neurologically stable or improved.
Partial response (PR): ≥ 50% decrease in size of enhancing tumor on consecutive MRI scans at least 1 month apart, corticosteroids stable or reduced, and neurologically stable or improved.
Progressive disease (PD): ≥ 25% increase in the size of enhancing tumor or any new tumor; or neurologically worse, and steroids stable or increased.
Stable disease (SD): Does not qualify for CR, PR, or PD.
|
From randomization to death or last follow-up. Patients were followed up to 62.9 months.
|
Agreement Between Local Interpretation and Central Interpretation of Standard MRI
Time Frame: baseline visit, week 2, after every 2 cycles of treatment, and at termination of treatment
|
Local and central interpretations of the standard MRI were assessed for progression and survival at all available imaging (baseline visit, week 2, and after every 2 cycles of treatment, and at termination of treatment).
Patients who suffer clinical progression without radiographic confirmation of progression were considered to have progressive disease in determination of PFS-6.
Subjects participated in the MR substudies regardless of therapeutic intervention
|
baseline visit, week 2, after every 2 cycles of treatment, and at termination of treatment
|
Accuracy of Local PFS 6-mo Interpretation Using Central Review PFS-6 as the Reference Standard
Time Frame: baseline visit, week 2, after every 2 cycles of treatment, and at termination of treatment
|
Local reads were treated as the test and central reads were treated as the reference standard.
Thus, a participant meeting the definition of progression on any standard MRI central interpretation (baseline visit, week 2, after every 2 cycles of treatment, and at termination of treatment) was considered positive for PFS-6.
Therefore, a true positive is defined as a positive local interpretation for a subject with a positive central read.
|
baseline visit, week 2, after every 2 cycles of treatment, and at termination of treatment
|
Correlation of Degree of Cerebral Blood Volume (CBV) and Lactate (Lac) to N-acetylaspartate (NAA) (Lac/NAA) Ratio
Time Frame: 2 weeks following initiation of protocol treatment (T1) and at 8 weeks following chemotherapy with bevacizumab (T2)
|
Aim not included in final (February 10, 2009) protocol (removed from section 2).
|
2 weeks following initiation of protocol treatment (T1) and at 8 weeks following chemotherapy with bevacizumab (T2)
|
Correlation of Degree of Cerebral Blood Volume (CBV) and Lactate (Lac) to Patient Response
Time Frame: 2 weeks following initiation of protocol treatment (T1)
|
Aim not included in final (February 10, 2009) protocol (removed from section 2)
|
2 weeks following initiation of protocol treatment (T1)
|
Predictive Value of CBV and Lac/NAA in Assessing 6-month Progression-free Survival
Time Frame: 2 weeks following initiation of protocol treatment (T1)
|
Aim not included in final (February 10, 2009) protocol (removed from section 2)
|
2 weeks following initiation of protocol treatment (T1)
|
Change in Perfusion MRI Markers at Week 2 as Predictors of 12mo Overall Survival (OS)
Time Frame: Baseline and 2 Weeks
|
To assess the potential role of perfusion MRI as a prognostic indicator for 12-month OS based on the change in MRI markers evaluated before treatment and 2 weeks following initiation of protocol treatment.
Percent change in mean tumor relative cerebral blood volume (rCBV) derived from dynamic susceptibility contrast (DSC) MRI normalized to white matter (nRCBV) and standardized rCBV (sRCBV) between baseline and week 2 are the prognostic indicators.
|
Baseline and 2 Weeks
|
Change in Perfusion MRI Markers at Week 8 as Predictors of 12mo Overall Survival (OS)
Time Frame: Baseline and 8 weeks
|
To assess the potential role of perfusion MRI as a prognostic indicator for 12-month OS based on the change in MRI markers evaluated before treatment and 8 weeks following initiation of protocol treatment.
Percent change in mean tumor relative cerebral blood volume (rCBV) derived from dynamic susceptibility contrast (DSC) MRI normalized to white matter (nRCBV) and standardized rCBV (sRCBV) between baseline and week 8 are the prognostic indicators.
|
Baseline and 8 weeks
|
Change in Perfusion MRI Markers at Week 16 as Predictors of 12mo Overall Survival (OS)
Time Frame: Baseline and 16 Weeks
|
To assess the potential role of perfusion MRI as a prognostic indicator for 12-month OS based on the change in MRI markers evaluated before treatment and 16 weeks following initiation of protocol treatment.
Percent change in mean tumor relative cerebral blood volume (rCBV) derived from dynamic susceptibility contrast (DSC) MRI normalized to white matter (nRCBV) and standardized rCBV (sRCBV) between baseline and week 16 are the prognostic indicators.
|
Baseline and 16 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark Gilbert, Radiation Therapy Oncology Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Astrocytoma
- Glioma
- Neoplasms, Neuroepithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Glioblastoma
- Recurrence
- Brain Neoplasms
- Gliosarcoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Topoisomerase I Inhibitors
- Antibodies
- Temozolomide
- Immunoglobulins
- Bevacizumab
- Irinotecan
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Immunoglobulin G
- Endothelial Growth Factors
- Camptothecin
Other Study ID Numbers
- NCI-2009-00743 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA021661 (U.S. NIH Grant/Contract)
- RTOG-0625 (Other Identifier: CTEP)
- ACRIN-6677 (Other Identifier: ACRIN)
- CDR0000528259 (Registry Identifier: CDR)
- RTOG 0625 (Other Identifier: Radiation Therapy Oncology Group)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Adult Glioblastoma
-
National Cancer Institute (NCI)CompletedAdult Anaplastic Astrocytoma | Adult Diffuse Astrocytoma | Adult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Adult Mixed Glioma | Adult Oligodendroglioma | Adult Pineal Gland AstrocytomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)TerminatedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
Michael Vogelbaum, MD, PhDNational Cancer Institute (NCI)TerminatedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult Gliosarcoma | Recurrent Adult Brain TumorUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)Radiation Therapy Oncology GroupCompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
-
National Cancer Institute (NCI)CompletedAdult Giant Cell Glioblastoma | Adult Glioblastoma | Adult GliosarcomaUnited States
Clinical Trials on Bevacizumab
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Serous Cystadenocarcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)NRG OncologyCompletedGlioblastoma | Gliosarcoma | Recurrent Glioblastoma | Oligodendroglioma | Giant Cell Glioblastoma | Recurrent Brain NeoplasmUnited States, Canada
-
M.D. Anderson Cancer CenterRecruitingStage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8 | Resectable Hepatocellular Carcinoma | Stage I Hepatocellular Carcinoma AJCC v8 | Stage IA Hepatocellular Carcinoma AJCC v8United States
-
National Cancer Institute (NCI)Active, not recruitingOvarian Endometrioid Adenocarcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Ovarian High Grade Serous Adenocarcinoma | Platinum-Resistant... and other conditionsUnited States, Canada
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Adenocarcinoma | Fallopian Tube Serous Adenocarcinoma | Ovarian Serous Adenocarcinoma | Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Stage IV Cervical Cancer AJCC v6 and v7 | Stage IVB Cervical Cancer AJCC v6 and v7United States
-
Northwestern UniversityNational Cancer Institute (NCI); Ipsen BiopharmaceuticalsCompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingStage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingMalignant Solid Neoplasm | Ovarian Endometrioid Adenocarcinoma | Ovarian Undifferentiated Carcinoma | Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Malignant Peritoneal Neoplasm | Endometrial Clear Cell Adenocarcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Merck Sharp & Dohme LLC; Celldex TherapeuticsRecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Endometrial Serous Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Platinum-Sensitive Ovarian Carcinoma | Recurrent Fallopian... and other conditionsUnited States